Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GBS Inc. (GBS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0700-0.0600 (-2.82%)
At close: 4:00PM EDT
2.0500 -0.02 (-0.97%)
After hours: 04:47PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.1300
Open2.1200
Bid2.0600 x 900
Ask2.1000 x 900
Day's Range2.0600 - 2.1300
52 Week Range1.9400 - 14.2400
Volume159,672
Avg. Volume721,149
Market Cap25.631M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    GBS Inc. Announces its Pre-Submission package is with the FDA

    NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA). The purpose of this pre-submission is to confirm with the FDA that GBS is following the proper steps to conduct the clinical studies enabling it to develop the glucos

  • GlobeNewswire

    GBS Inc. to Present at Upcoming September Virtual Investor Conferences

    H.C. Wainwright 23rd Global Investor Conference: September 13th - 15th Benzinga Healthcare Small Cap Conference: September 29th - 30th NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced its participation in the following investor conferences in the month of September and invites investors to join virtually. H.C. Wainwrigh

  • Benzinga

    21 Stocks Moving in Wednesday's Pre-Market Session

    Gainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-19 diagnostic with Harvard's Wyss Institute. Field Trip Health Ltd. (NASDAQ: FTRP) shares rose 30% to $6.25 in pre-market trading. HC Wainwright & Co. initiated coverage on Field Trip Health with a Buy rating and announced a price target of $20. Focus Universal Inc. (NASDAQ: FCUV) rose 25.1% to $6.38 in pre-market tradin

Advertisement
Advertisement